共 50 条
- [21] Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell TherapyBLOOD, 2022, 140Raj, SandeepPerales, Miguel-AngelFein, Joshua A.Tomas, Ana AlarconBatlevi, Connie LeeDe Lapuerta, Magdalena CoronaDahi, Parastoo B.Danylesko, IvettaFried, ShalevFunnell, TylerGiralt, Sergio A.Jacoby, EladKedmi, MeiravLin, Richard J.Nagler, ArnonNath, KarthikParascondola, AllisonPalomba, M. LiaSalles, GillesScordo, MichaelShah, Gunjan L.Shem-Tov, NogaShimoni, AvichaiSlingerland, JohnWalji, MoneezaYerushalmi, RonitAvigdor, Abrahamvan den Brink, Marcel R. M.Shouval, Roni
- [23] Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patientsFRONTIERS IN IMMUNOLOGY, 2022, 13Qu, ChangjuZou, RuiWang, PengZhu, QianKang, LiqingPing, NanaXia, FanLiu, HailingKong, DanqingYu, LeiWu, DepeiJin, Zhengming
- [24] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell LymphomaBLOOD, 2018, 132Sano, DahliaNastoupil, Loretta J.Fowler, Nathan H.Fayad, LuisHagemeister, F. B.Lee, Hun JuSamaniego, FelipeWang, MichaelRodriguez, Maria AlmaIyer, Swaminathan P.Parmar, SimritSteiner, RaphaelNair, RanjitAdkins, SherryArafat, SaraRao, AhalyaVallejo, LilianaHawkins, MishaChen, YimingWestin, Jason R.Neelapu, Sattva S.
- [25] CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and MyelomaBLOOD, 2021, 138D'Ovidio, Tyler J.Ciccolini, KathrynKalac, MatkoOsman, KerenSteinberg, Amir
- [26] Higher relative extranodal lymphoma burden is associated with shorter progression-free survival after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-Cell lymphomaONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 258 - 258Buecklein, VBlumenberg, VWinkelmann, M.Ackermann, J.Froelich, L.Schmidt, C.Hildebrand, F.Rejeski, K.Ruzicka, M.Mueller, N.von Baumgarten, L.Schoeberl, F.Hildebrandt, M.Humpe, A.Hoster, E.von Bergwelt, M.Kunz, W. G.Subklewe, M.
- [27] T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell LymphomaFRONTIERS IN IMMUNOLOGY, 2022, 13Wang, JiachenShen, KefengMu, WeiLi, WeigangZhang, MeilanZhang, WeiLi, ZheGe, TongZhu, ZhoujieZhang, ShangkunChen, CaixiaXing, ShugangZhu, LiChen, LitingWang, NaHuang, LiangLi, DengjuXiao, MinZhou, Jianfeng
- [28] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphomaHEMASPHERE, 2024, 8 (08):Gong, Inna Y.Tran, DaisySaibil, SamuelLaister, Rob C.Kuruvilla, John
- [29] Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell LymphomaJOURNAL OF BLOOD MEDICINE, 2021, 12 : 775 - 783Castaneda-Puglianini, OmarChavez, Julio C.
- [30] Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell LymphomaAMERICAN JOURNAL OF HEMATOLOGY, 2024,Thiruvengadam, Swetha KambhampatiMerryman, ReidWang, YanGaulin, CharlesBezerra, EvandroVoorhees, TimothySeshadri, Madhav R.Falade, AyoHabib, AlmaAyers, Amy A.Bailey, MegumiBrown, AnnetteBailey, NeilPatel, KrishAndreadis, Charalambos B.Kittai, Adam S.Jacobson, CaronPalmer, JoycelynneForman, Stephen J.Nastoupil, LorettaBudde, Lihua E.